...
首页> 外文期刊>The Lancet >Chronic myeloid leukaemia
【24h】

Chronic myeloid leukaemia

机译:慢性粒细胞白血病

获取原文
获取原文并翻译 | 示例

摘要

In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of a fatal disease to a disorder amenable simply to lifelong oral medication and compatible with a normal lifespan. This change has been made possible by a deep understanding of the molecular pathogenesis and a determination to develop targeted and selective drugs. This Seminar summarises the presentation, pathophysiology, diagnosis and monitoring technology, treatment options, side-effects, and outcomes of chronic myeloid leukaemia, and discusses the possibility of cure-ie, stable undetectable or low level disease in the absence of medication. Chronic myeloid leukaemia continues to instruct us in the mechanisms of leukaemogenesis and provides hope not only for similar developments in management of other malignancies, but also for the remarkable speed with which these can move from bench to bedside.
机译:在不到10年的时间里,慢性粒细胞白血病的预后已经从致命疾病转变为一种可以简单地终身服药并与正常寿命相适应的疾病。通过对分子发病机理的深刻理解以及对开发靶向药物和选择性药物的决心,使得这一改变成为可能。该研讨会总结了慢性粒细胞白血病的表现,病理生理学,诊断和监测技术,治疗选择,副作用和结果,并讨论了在没有药物治疗的情况下治愈,稳定,无法检测或低水平疾病的可能性。慢性粒细胞白血病继续指导我们了解白血病的发生机制,不仅为处理其他恶性肿瘤的类似进展提供了希望,而且还为这些恶性肿瘤从实验台向床旁运动的惊人速度提供了希望。

著录项

  • 来源
    《The Lancet 》 |2015年第9976期| 共13页
  • 作者

    Apperley Jane F.;

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号